Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO – Get Free Report) insider David Hochman bought 5,000 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were bought at an average cost of $3.83 per share, for a total transaction of $19,150.00. Following the purchase, the insider owned 1,064,029 shares of the company’s stock, valued at approximately $4,075,231.07. The trade was a 0.47% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Orchestra BioMed Price Performance
Shares of NASDAQ:OBIO traded up $0.04 during trading on Tuesday, hitting $3.87. 292,725 shares of the company were exchanged, compared to its average volume of 252,075. The business’s 50 day moving average is $4.18 and its 200-day moving average is $4.28. The company has a market capitalization of $231.62 million, a P/E ratio of -3.89 and a beta of 0.51. The company has a quick ratio of 7.01, a current ratio of 7.03 and a debt-to-equity ratio of 0.35. Orchestra BioMed Holdings, Inc. has a 1-year low of $2.20 and a 1-year high of $5.42.
Orchestra BioMed (NASDAQ:OBIO – Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.07. The company had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.92 million. Orchestra BioMed had a negative net margin of 166.96% and a negative return on equity of 157.46%. Equities analysts forecast that Orchestra BioMed Holdings, Inc. will post -1.47 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Read Our Latest Analysis on Orchestra BioMed
Institutional Trading of Orchestra BioMed
Large investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new stake in Orchestra BioMed during the 2nd quarter worth about $50,000. XTX Topco Ltd acquired a new stake in Orchestra BioMed during the 2nd quarter worth about $45,000. Creative Planning acquired a new stake in shares of Orchestra BioMed in the 2nd quarter valued at about $40,000. Bank of America Corp DE grew its stake in shares of Orchestra BioMed by 200.7% in the 1st quarter. Bank of America Corp DE now owns 52,761 shares of the company’s stock valued at $224,000 after buying an additional 35,214 shares during the period. Finally, Rice Hall James & Associates LLC acquired a new stake in shares of Orchestra BioMed in the 1st quarter valued at about $81,000. 53.20% of the stock is currently owned by institutional investors and hedge funds.
Orchestra BioMed Company Profile
Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.
Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.
Featured Stories
- Five stocks we like better than Orchestra BioMed
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Receive News & Ratings for Orchestra BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchestra BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
